Imunon, Inc.

IMNN

Healthcare|Biotechnology|US

$0.84

-0.06 (-6.16%)

DCF Value

$3.07

Tangible Book / Share

$0.80

Cash / Share

$1.31

Next Earnings Report

Nov 12, 2026

EPS est. -$0.61

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Oct 28, 2026 (S-1/A). Possible dilution.

Upcoming Data Readouts (2)

Jun 2027

Est. completion

P1P2Ovarian Cancer

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981n=30

Oct 2032

Est. completion

P3Epithelial Ovarian Cancer

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025n=500

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2024

P1P2

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT03393884

Recent Press Releases

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

Nov 6, 2026 · GlobeNewsWire

IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026

Nov 2, 2026 · GlobeNewsWire

IMUNON Announces Strategic Sale of ThermoDox®

Oct 21, 2026 · GlobeNewsWire

IMUNON to Participate in Upcoming Investor Conferences

Oct 8, 2026 · GlobeNewsWire

IMUNON Converts $1.2 Million of Debt-to-Equity

Sep 29, 2026 · GlobeNewsWire

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

Sep 24, 2026 · GlobeNewsWire

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Sep 22, 2026 · GlobeNewsWire

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Sep 10, 2026 · GlobeNewsWire

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

Sep 9, 2026 · GlobeNewsWire

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Aug 26, 2026 · GlobeNewsWire

SEC Filings (71)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 28, 2026	S-1/A	IPO / offering registration	Document Index
Oct 27, 2026	S-1	IPO / offering registration	Document Index
Oct 27, 2026	8-K	Material event	Document Index
Oct 21, 2026	8-K	Material event	Document Index
Sep 29, 2026	8-K	Material event	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 11, 2026	8-K	Material event	Document Index
Aug 11, 2026	10-Q	Quarterly report	Document Index
Aug 11, 2026	8-K	Material event	Document Index
Jun 30, 2026	8-K	Material event	Document Index
Jun 17, 2026	S-8	Employee stock plan	Document Index
Jun 16, 2026	8-K	Material event	Document Index
Jun 4, 2026	8-K	Material event	Document Index
May 15, 2026	SC 13G/A	Passive 5%+ stake	Document Index
May 12, 2026	10-Q	Quarterly report	Document Index
May 12, 2026	8-K	Material event	Document Index
May 4, 2026	ARS	Annual report to holders	Document Index
May 4, 2026	8-K	Material event	Document Index
May 4, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Mar 31, 2026	10-K	Annual report	Document Index
Mar 31, 2026	8-K	Material event	Document Index
Mar 23, 2026	8-K	Material event	Document Index
Mar 23, 2026	424B5	Offering prospectus	Document Index
Feb 17, 2026	SC 13G	Passive 5%+ stake	Document Index
Feb 5, 2026	8-K	Material event	Document Index
Jan 7, 2026	8-K	Material event	Document Index
Dec 31, 2025	424B5	Offering prospectus	Document Index
Dec 31, 2025	8-K	Material event	Document Index
Nov 13, 2025	S-8	Employee stock plan	Document Index
Nov 13, 2025	10-Q	Quarterly report	Document Index
Nov 13, 2025	8-K	Material event	Document Index
Aug 28, 2025	8-K	Material event	Document Index
Aug 13, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Aug 12, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Aug 5, 2025	10-Q	Quarterly report	Document Index
Aug 5, 2025	8-K	Material event	Document Index
Jul 28, 2025	8-K	Material event	Document Index
Jul 23, 2025	8-K	Material event	Document Index
Jul 22, 2025	8-K	Material event	Document Index
Jul 22, 2025	424B5	Offering prospectus	Document Index